ASH 2024: New Research, Data Drive Progress in Myelofibrosis
Phase‑III data from FREEDOM2, BOREAS, and MANIFEST‑2, together with a real‑world analysis, demonstrate that fedratinib, navtemadlin, and pelabresib plus ruxolitinib offer superior spleen volume reduction, symptom improvement, and potential disease‑modifying effects in myelofibrosis, while also highlighting the impact of anemia on outcomes with ruxolitinib.
At ASH 2024, key phase‑III trials—FREEDOM2, BOREAS, and MANIFEST‑2—presented data showing that fedratinib, navtemadlin, and pelabresib plus ruxolitinib improve spleen volume reduction, symptom scores, and bone‑marrow fibrosis in myelofibrosis patients. A retrospective real‑world study further quantified the detrimental impact of anemia on overall survival in patients treated with ruxolitinib. These findings provide clinicians with evidence to tailor second‑line and combination therapies and address unmet needs such as anemia management.
The evidence directs therapeutic decisions in myelofibrosis, potentially improving survival, symptom control, and quality of life by offering effective second‑line options and clarifying the role of anemia in treatment outcomes.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Primary Myelofibrosis
- Extended Access of Momelotinib in Adults With Myelofibrosis
- Appraising the Use of JAK Inhibitors in Treating Myelofibrosis
- The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non‑JAK Inhibitor Therapies
- Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis